Our study shows that OPA1 ablation or inhibition with MYLS22, a specific, nontoxic small molecule inhibitor identified in our laboratory [39] decreases breast cancer cell migration, proliferation, adhesion and invasion. Here, OPA1 is linked to breast cancer.